Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol Dosage Frequency Impact on Sleep in Infantile Hemangiomas
NCT05479123Phase 4Terminated
- Sponsor
- UTHealth Houston
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of propranolol in infantile hemangioma (IH) (3 arms), sponsored by UTHealth Houston. Primary endpoint: Number of Sleep Awakenings Per Night as Assessed by One-Item in the Brief Infant Sleep Questionnaire (BISQ) at 6 months. Started Jun 2022; status: terminated.
02
Drugs
propranolol
03
Conditions
infantile hemangioma (IH)
Beyond the preview
Go deeper on NCT05479123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479123.